Navigation Links
Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
Date:3/17/2008

phoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing, progress and anticipated completion of Nuvelo's clinical stage and research programs, the anticipated availability of top-line data, projected operating expenses and cash usage and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's annual report on Form 10-K for the year ended December 31, 2007 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
2. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
3. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
4. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
5. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
6. Synbiotics Corporation Announces Human Submission for FluDetect(R)
7. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
8. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
9. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
10. Inclinix Announces New Patent for Expert System Platform
11. Genzyme Announces Presentation of New Positive Data on Carticel(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... , Spanje, July 4, 2015 ... harsmicrosferen aan eerstelijns chemotherapie voor patiënten met ... (mCRC) verlengt de progressievrije overleving in dat ... gemetastaseerde colorectale kanker (mCRC) die alleen binnen ... gezien in progressievrije overleving (PFS) in de ...
(Date:7/3/2015)... , July 4, 2015 A ... of hypertension, diabetes and thyroid disorders in Central and ... educational platforms and a major conference dedicated to these ... Manage Diabetes Online , Manage Hypertension Online ... developed and operated by EXCEMED - combine ...
(Date:7/3/2015)... A global continuing medical education ... thyroid disorders in Latin America ... dedicated to these diseases.      (Logo: http://photos.prnewswire.com/prnh/20150630/227033) ... Manage Hypertension Online and Manage Thyroid Online ... - combine the world,s top expertise with dynamic ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Combating Three Major Chronic Diseases in Central and South-East Asia With Medical Education 2Combating Three Major Chronic Diseases in Latin America With Medical Education 2
... LONDON, March 19, 2007-AstraZeneca today announced that ... results from the ARISE (Aggressive Reduction of ... which studied,AGI-1067, an investigational anti-atherosclerotic agent with,antioxidant ... disease (CAD). ,The ARISE trial did not ...
... /PRNewswire-FirstCall/ --,Nuvelo, Inc. today announced that clinical data ... MACE)/TIMI 32 Phase,2 trial looking at recombinant nematode ... coronary syndromes,(NSTE-ACS) will be presented in a V-poster ... Session taking place in New,Orleans, LA, March 24-27, ...
Cached Medicine Technology:Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet,Primary Endpoint 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 3
(Date:7/6/2015)... ... July 06, 2015 , ... ... Spa industries, announces the return of its complimentary educational webinar series ... medical business leaders creates success for their clients through targeted marketing, sales, digital ...
(Date:7/6/2015)... Beach, Virginia (PRWEB) , ... July 06, 2015 ... ... States choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction ... country. For a particular demographic, however, fat reduction has become more than a ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce ... Teaching Award on behalf of the department of Family Practice. , “This award is ... be practicing in. The technology is changing so rapidly and we are also developing ...
(Date:7/6/2015)... ... July 06, 2015 , ... doTERRA, the leading global ... executive management team. Most recently, Jowers held the position as Director of the Hinckley ... After spending a decade building the institute, Jowers states that he was ready for ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... redesigned site allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with ... survived the same cancer. , “Receiving a cancer diagnosis is often the most ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... UPTON, NY - A new study by scientists at the ... Norway suggests that the benefits of moderately increased exposure to ... against the lethal effects of many forms of cancer and ... cancer in populations deficient in vitamin D. The study will ...
... activate abnormally in malignant cells , , MONDAY, Jan. 7 (HealthDay ... genes that play a role in cell division, and ... of those genes show an abnormal pattern of activation in ... issue of the Proceedings of the National Academy of ...
... University Center for Clinical and Translational Science (CCTS) has ... Eight Rockefeller researchers will each receive $25,000 from the ... if successful, might lead to clinical trials. The CCTS ... established through funds from a Clinical and Translational Science ...
... caused by aging, can also be caused by pesticides ... that trichloroethylene (TCE) is a risk factor for parkinsonism, ... Parkinsons disease. TCE is a chemical widely used in ... water and soil due to runoff from manufacturing sites ...
... experts are split on the need for supplements , , MONDAY, ... D -- sourced through sunlight, some foods and supplements ... such as heart attack and stroke, U.S. researchers report. , ... Heart Study included 1,739 people, average age 59, living in ...
... suffering from a form of asphyxia at birth have ... a lifetime of debilitating and costly health complications, according ... , The findings, which appear today in the January ... technique, that better availability and placement of CoolCaps within ...
Cached Medicine News:Health News:More sun exposure may be good for some people 2Health News:More sun exposure may be good for some people 3Health News:Team Finds 118 Genes That Might Play Role in Cancer 2Health News:Rockefeller University's Center for Clinical and Translational Science funds pilot studies 2Health News:Trichloroethylene is a risk factor for parkinsonism 2Health News:Trichloroethylene is a risk factor for parkinsonism 3Health News:Low Vitamin D Linked to Heart Risk 2Health News:Low Vitamin D Linked to Heart Risk 3Health News:Better access to cool caps improves outcomes, lowers cost of treating asphyxia in newborns 2
... an enzymatic cleanser for automated and semi-automated ... 475ml bottle has a flip-top spout for ... that require manual addition of an enzyme ... of this product. The shelf life of ...
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
... is a nucleated red blood cell (nRBC) control ... Coulter LH 750/LH 755 hematology analyzer in its ... for the Coulter LH 750/LH 755. nRBC-Chex for ... cap-pierceable vials. nRBC-Chex for LH has a 75-day ...
Medicine Products: